
Opinion|Videos|March 31, 2025
Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy
Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after immune-oncology (IO)–based therapy.
Advertisement
Advertisement
Related to this article

A Columbia nurse scientist shares her takeaways from the 2026 ASCO Quality Care Symposium, from geriatric assessment to care across the age span.

A patient, a caregiver, nurses, an NP, and an oncologist discuss rash prevention, dose holds, cost, and trial eligibility with oral daraxonrasib.

In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.

Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.

Lisa Carter-Bawa, PhD, MPH, APRN, explains how nurses can counter lung cancer fatalism by pairing honesty with hope and using teach-back.

Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.

As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Patients, Nurses Share What Daraxonrasib Means in Practice
2
ASCO Quality Care 2026: Closing the Gap Between Evidence and Practice
3
For Young Women With Cancer, Fertility Choices Evolve Beyond Diagnosis
4
Income, Age Linked to Breast Cancer Care Delays in Women 40 and Under
5

